StrokeRACECATNCT02795962
Direct Transfer to an Endovascular Center Compared to Transfer to the Closest Stroke Center in Acute Stroke Patients With Suspected Large Vessel Occlusion
A study testing Direct transfer to an Endovascular Center in people with Stroke, run by Fundacio Ictus Malaltia Vascular at 12 sites in Spain.
Trial summary
To evaluate the hypothesis that direct transfer to an Endovascular Stroke Center, compared to transfer to the closest Local Stroke Center, offers a better outcome in the distribution of the modified Rankin Scale scores at 90 days in acute ischemic stroke patients with clinically suspected Large Vessel Occlusion… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Stroke
- What is being tested?
- Direct transfer to an Endovascular Center
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,401 participants
- Where
- 12 sitesSpain
- Study dates
- 1 Mar 2017to 1 Oct 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Suspected LVO acute stroke patients identified by a RACE scale score >4 at the pre-hospital setting, that is evaluated by EMS professionals when attending patients, in non-stroke ready centers or primary health centers, previous to the transfer to a stroke center.
- Patients located in geographical areas in which the reference stroke center is a hospital not capable to offer endovascular treatment (Primary stroke Center or Telestroke Center).
- Estimated arrival time at an EVT-SC <7 hours from symptom onset. Symptom onset is defined as point in time the patient was last seen well (at baseline).
- No significant pre-stroke functional disability (modified Rankin scale 0 - 2)
- Age ≥18
- Deferred informed consent obtained from patient or acceptable patient surrogate (after the acute phase, as permission to use clinical data within a clinical registry)
Who cannot join
- Patients in a coma (NIHSS item of consciousness >1)
- Patients with unstable clinical status who require emergent life support care
- Serious, advanced, or terminal illness with anticipated life expectancy of less than 6 month.
- Suspected LVO acute stroke patients identified at the Emergency Department of a stroke center
- Subject participating in a study involving an investigational drug or device that would impact this study.
- Patients with a pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations. This excludes patients who are severely demented, require constant assistance in a nursing home type setting or who live at home but are not fully independent in activities of daily living (toileting, dressing, eating, cooking and preparing meals, etc.)
- Unlikely to be available for 90-day follow-up (e.g. no fixed home address, visitor from overseas).
Trial locations and contacts
12 sites in 1 country.
12 sites in 1 country
Spain12 sites
Hospital Germans Trias i Pujol
Badalona
Hospital Bellvitge
Barcelona
Hospital Clínic
Barcelona
Hospital Mar
Barcelona
Hospital Moisés Broggi
Barcelona
Hospital Santa Creu i Sant Pau
Barcelona
Hospital Vall d'Hebrón
Barcelona
Hospital Josep Trueta
Girona
Hospital Arnau Vilanova
Lleida
Hospital Althaia
Manresa
Mutua Terrassa
Terrassa
Hospital Verge de la Cinta
Tortosa
About this study
Official title: A Trial Comparing Transfer to the Closest Local Stroke Center vs. Direct Transfer to Endovascular Stroke Center of Acute Stroke Patients With Suspected Large Vessel Occlusion in the Catalan Territory.
To evaluate the hypothesis that direct transfer to an Endovascular Stroke Center, compared to transfer to the closest Local Stroke Center, offers a better outcome in the distribution of the modified Rankin Scale scores at 90 days in acute ischemic stroke patients with clinically suspected Large Vessel Occlusion identified by Emergency Medical Services (EMS).
Read the detailed description
Prospective, multicenter, cluster randomized controlled, usual care conditions, open, blinded-endpoint trial of acute stroke patients with suspected acute large vessel occlusion (LVO) identified by EMS at first assistance on the field, in which two strategies will be compared: transfer to the closest local stroke center (Local-SC) Vs. direct transfer to an endovascular stroke center (EVT-SC).
The RACE scale (Rapid Arterial oCclusion Evaluation) will be used as a prehospital screening tool to identify acute stroke patients with suspicion of LVO. Upon candidate identification, EMS will contact a stroke neurologist on call using a prehospital telestroke system who will confirm inclusion criteria and will allocate the subjects to a specific intervention according to a pre-established temporal sequence. Allocation will account for 3 strata: time band (two groups of 12 hours), territory (metropolitan versus provincial area) and week day (working versus weekend day).
Subjects will be followed up to 90 days post-randomization.
- Conditions
- Stroke
- Being tested
- Direct transfer to an Endovascular Center
- Keywords
- Endovascular Procedures, Emergency Medical Services
- Medical subject headings
- Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Direct transfer to an Endovascular CenterOther
Cluster randomized controlled study: allocation to active or no intervention arm will be performed accordingly to a pre-established temporal sequence
| Study group | Role | What they receive |
|---|---|---|
| Transfer to an Endovascular Center | Active comparator | Acute stroke patients with suspected acute large vessel occlusion identified by EMS at first assistance on the field will be directly transferred to the nearest Endovascular Center bypassing the Local Stroke Center. Receives: Other: Direct transfer to an Endovascular Center |
| Transfer to the Local Stroke Center | No intervention | Acute stroke patients with suspected acute large vessel occlusion identified by EMS at first assistance on the field will be transferred to the Local Stroke Center as done accordingly with the current stroke code protocol. |
What is being measured
The primary outcome is the main question the study is designed to answer.
modified Rankin Scale score (shift analysis)
Modified Rankin Scale score in ischemic stroke patients as evaluated through a structured telephone-based interview performed by a central assessor who is blinded to group assignment.
Measured: 90 days
Secondary outcomes (9)
Mortality in all patients
Mortality in all patients included
Measured: 90 days
Mortality in hemorrhagic stroke patients
Mortality in hemorrhagic stroke patients
Measured: 90 days
Clinical deterioration requiring orotracheal intubation during transfers
Orotracheal intubation during transfers
Measured: 8 hours
Clinical deterioration
Clinical deterioration (≥4 points on the NIHSS)
Measured: 24 hours
Reperfusion therapies
Proportion of patients receiving iv tPA and endovascular treatment within the first 8h from symptom onset
Measured: 8 hours
Time from symptom onset to reperfusion therapies
Time from symptom onset to iv tPA administration (for patients treated with iv tPA) and to groin puncture (for patients treated with endovascular).
Measured: 8 hours
Subgroup analysis
Distribution of the modified Rankin Scale score at 90 days (shift analysis) in the following subgroups:
- Ischemic / hemorrhagic
- Patients eligible for iv t-PA vs. non iv t-PA eligible when attended by EMS (within time window considering transfer time to the nearest SC, no formal contraindications as recent major surgery or anticoagulation)
- Patients treated with EVT
Measured: 90 days
Clinical benefit of direct vs. local transfer accordingly with time and distance to the Endovascular Center
To analyze whether an inflection point exists with respect to time from onset to arrival at the Endovascular Center beyond which transfer to a Local-SC is beneficial or equivalent.
Measured: 90 days
Dramatic early favorable response
Dramatic early favorable response as determined by an NIHSS (National Institute of Health Stroke Scale) of 0-2 or NIHSS improvement ≥ 8 points in ischemic stroke and hemorrhagic stroke patients.
Measured: 24 (-2/+12 hours)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jun 2016 (estimated)
- Study start1 Mar 2017
- Primary completion1 Oct 2020
- Study completion1 Oct 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (7)Papers the sponsor has linked to this study.
- Other trials for StrokeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 1,401 participants (actual)
Sponsor and investigators
- Lead sponsor
- Fundacio Ictus Malaltia Vascular
- Sponsor type
- University, hospital or other
- Collaborators
- Medtronic, Anagram-ESIC, UPC, BioClever 2005 S.L.
- Responsible party
- Sponsor
- Investigators
- Marc Ribó, PhD, Principal investigator, Hospital Universitari Vall d'Hebrón, Barcelona, SpainSonia Abilleira, PhD, Principal investigator, Pla Director Malaltia Vascular Cerebral. Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)Natalia Pérez de la Ossa, PhD, Principal investigator, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02795962
- Sponsor's protocol ID
- RACECAT
- Acronym
- RACECAT
- Status last verified
- Mar 2021
- First submitted
- 1 Jun 2016
- Last updated
- 16 Mar 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Sapiro N, Kamal N, Abilleira S, Jimenez X, Ramos-Pachon A, Garcia-Tornel A, Perez de la Ossa N, Ribo M, Hill MD, Holodinsky JK. Modeling Prehospital Transportation for Patients With Suspected Acute Ischemic Stroke due to Large Vessel Occlusion: A Validation Study Using the RACECAT Trial Data. Stroke. 2026 Aug;57(8):2340-2347. doi: 10.1161/STROKEAHA.125.054668. Epub 2026 May 13.
PubMed 42125807Ramos-Pachon A, Rodriguez-Luna D, Marti-Fabregas J, Millan M, Bustamante A, Martinez-Sanchez M, Serena J, Terceno M, Vera-Caceres C, Camps-Renom P, Prats-Sanchez L, Rodriguez-Villatoro N, Cardona-Portela P, Urra X, Sola S, Del Mar Escudero M, Salvat-Plana M, Ribo M, Abilleira S, Perez de la Ossa N, Silva Y; RACECAT Trial Investigators. Effect of Bypassing the Closest Stroke Center in Patients with Intracerebral Hemorrhage: A Secondary Analysis of the RACECAT Randomized Clinical Trial. JAMA Neurol. 2023 Oct 1;80(10):1028-1036. doi: 10.1001/jamaneurol.2023.2754.
PubMed 37603325Garcia-Tornel A, Flores A, Terceno M, Cardona P, Amaro S, Gomis M, Zaragoza J, Krupinski J, Gomez-Choco M, Mas N, Cocho D, Catena E, Purroy F, Deck M, Rubiera M, Pagola J, Rodriguez-Luna D, Juega J, Rodriguez-Villatoro N, Molina CA, Soro C, Jimenez X, Salvat-Plana M, Davalos A, Jovin TG, Abilleira S, Perez de la Ossa N, Ribo M; RACECAT Trial Investigators. Association of Time of Day With Outcomes Among Patients Triaged for a Suspected Severe Stroke in Nonurban Catalonia. Stroke. 2023 Mar;54(3):770-780. doi: 10.1161/STROKEAHA.122.041013. Epub 2023 Feb 27.
PubMed 36848432Garcia-Tornel A, Millan M, Rubiera M, Bustamante A, Requena M, Dorado L, Olive-Gadea M, Jimenez X, Soto A, Querol M, Hernandez-Perez M, Gomis M, Cardona P, Urra X, Purroy F, Silva Y, Ustrell X, Esteve P, Salvat-Plana M, Gallofre M, Molina C, Davalos A, Jovin T, Abilleira S, Ribo M, Perez de la Ossa N; RACECAT Trial Investigators. Workflows and Outcomes in Patients With Suspected Large Vessel Occlusion Stroke Triaged in Urban and Nonurban Areas. Stroke. 2022 Dec;53(12):3728-3740. doi: 10.1161/STROKEAHA.122.040768. Epub 2022 Oct 19.
PubMed 36259411Garcia-Tornel A, Sero L, Urra X, Cardona P, Zaragoza J, Krupinski J, Gomez-Choco M, Sala NM, Catena E, Palomeras E, Serena J, Hernandez-Perez M, Boned S, Olive-Gadea M, Requena M, Muchada M, Tomasello A, Molina CA, Salvat-Plana M, Escudero M, Jimenez X, Davalos A, Jovin TG, Purroy F, Abilleira S, Ribo M, de la Ossa NP; RACECAT trial investigators. Workflow Times and Outcomes in Patients Triaged for a Suspected Severe Stroke. Ann Neurol. 2022 Dec;92(6):931-942. doi: 10.1002/ana.26489. Epub 2022 Sep 7.
PubMed 36053966Perez de la Ossa N, Abilleira S, Jovin TG, Garcia-Tornel A, Jimenez X, Urra X, Cardona P, Cocho D, Purroy F, Serena J, San Roman Manzanera L, Vivanco-Hidalgo RM, Salvat-Plana M, Chamorro A, Gallofre M, Molina CA, Cobo E, Davalos A, Ribo M; RACECAT Trial Investigators. Effect of Direct Transportation to Thrombectomy-Capable Center vs Local Stroke Center on Neurological Outcomes in Patients With Suspected Large-Vessel Occlusion Stroke in Nonurban Areas: The RACECAT Randomized Clinical Trial. JAMA. 2022 May 10;327(18):1782-1794. doi: 10.1001/jama.2022.4404.
PubMed 35510397Abilleira S, Perez de la Ossa N, Jimenez X, Cardona P, Cocho D, Purroy F, Serena J, Roman LS, Urra X, Vilaro M, Cortes J, Gonzalez JA, Chamorro A, Gallofre M, Jovin T, Molina C, Cobo E, Davalos A, Ribo M. Transfer to the Local Stroke Center versus Direct Transfer to Endovascular Center of Acute Stroke Patients with Suspected Large Vessel Occlusion in the Catalan Territory (RACECAT): Study protocol of a cluster randomized within a cohort trial. Int J Stroke. 2019 Oct;14(7):734-744. doi: 10.1177/1747493019852176. Epub 2019 May 29.
PubMed 31142219
Study at a glance
From the registry record, last updated by the sponsor on 16 Mar 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Trial Comparing Transfer to the Closest Local Stroke Center vs. Direct Transfer to Endovascular Stroke Center of Acute Stroke Patients With Suspected Large Vessel Occlusion in the Catalan Territory.
- ClinicalTrials.gov ID
- NCT02795962
- Acronym / sponsor ID
- RACECAT / RACECAT
- Conditions
- Stroke
- Keywords
- Endovascular Procedures, Emergency Medical Services
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,401 participants (actual)
- Lead sponsor
- Fundacio Ictus Malaltia VascularUniversity, hospital or other
- Collaborators
- Medtronic, Anagram-ESIC, UPC, BioClever 2005 S.L.
- Study start
- 1 Mar 2017 (actual)
- Primary completion
- 1 Oct 2020 (actual)
- Study completion
- 1 Oct 2020 (actual)
- First posted
- 10 Jun 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To evaluate the hypothesis that direct transfer to an Endovascular Stroke Center, compared to transfer to the closest Local Stroke Center, offers a better outcome in the distribution of the modified Rankin Scale scores at 90 days in acute ischemic stroke patients with clinically suspected Large Vessel Occlusion identified by Emergency Medical Services (EMS).
Detailed description
Prospective, multicenter, cluster randomized controlled, usual care conditions, open, blinded-endpoint trial of acute stroke patients with suspected acute large vessel occlusion (LVO) identified by EMS at first assistance on the field, in which two strategies will be compared: transfer to the closest local stroke center (Local-SC) Vs. direct transfer to an endovascular stroke center (EVT-SC).
The RACE scale (Rapid Arterial oCclusion Evaluation) will be used as a prehospital screening tool to identify acute stroke patients with suspicion of LVO. Upon candidate identification, EMS will contact a stroke neurologist on call using a prehospital telestroke system who will confirm inclusion criteria and will allocate the subjects to a specific intervention according to a pre-established temporal sequence. Allocation will account for 3 strata: time band (two groups of 12 hours), territory (metropolitan versus provincial area) and week day (working versus weekend day).
Subjects will be followed up to 90 days post-randomization.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Transfer to an Endovascular Center | Active comparator | Other: Direct transfer to an Endovascular CenterAcute stroke patients with suspected acute large vessel occlusion identified by EMS at first assistance on the field will be directly transferred to the nearest Endovascular Center bypassing the Local Stroke Center. |
| Transfer to the Local Stroke Center | No intervention | –Acute stroke patients with suspected acute large vessel occlusion identified by EMS at first assistance on the field will be transferred to the Local Stroke Center as done accordingly with the current stroke code protocol. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Suspected LVO acute stroke patients identified by a RACE scale score >4 at the pre-hospital setting, that is evaluated by EMS professionals when attending patients, in non-stroke ready centers or primary health centers, previous to the transfer to a stroke center.
- Patients located in geographical areas in which the reference stroke center is a hospital not capable to offer endovascular treatment (Primary stroke Center or Telestroke Center).
- Estimated arrival time at an EVT-SC <7 hours from symptom onset. Symptom onset is defined as point in time the patient was last seen well (at baseline).
- No significant pre-stroke functional disability (modified Rankin scale 0 - 2)
- Age ≥18
Key exclusion criteria (7 listed)
- Patients in a coma (NIHSS item of consciousness >1)
- Patients with unstable clinical status who require emergent life support care
- Serious, advanced, or terminal illness with anticipated life expectancy of less than 6 month.
- Suspected LVO acute stroke patients identified at the Emergency Department of a stroke center
- Subject participating in a study involving an investigational drug or device that would impact this study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Direct transfer to an Endovascular CenterCluster randomized controlled study: allocation to active or no intervention arm will be performed accordingly to a pre-established temporal sequence | Other | Transfer to an Endovascular Center |
Primary outcome
modified Rankin Scale score (shift analysis)
Time frame: 90 days
Modified Rankin Scale score in ischemic stroke patients as evaluated through a structured telephone-based interview performed by a central assessor who is blinded to group assignment.
9 secondary outcomes
Mortality in all patients
Time frame: 90 days
Mortality in hemorrhagic stroke patients
Time frame: 90 days
Clinical deterioration requiring orotracheal intubation during transfers
Time frame: 8 hours
Clinical deterioration
Time frame: 24 hours
Reperfusion therapies
Time frame: 8 hours
Time from symptom onset to reperfusion therapies
Time frame: 8 hours
Subgroup analysis
Time frame: 90 days
Clinical benefit of direct vs. local transfer accordingly with time and distance to the Endovascular Center
Time frame: 90 days
Dramatic early favorable response
Time frame: 24 (-2/+12 hours)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Mar 2021.
- Derived from this study: PubMed 42125807Sapiro N, Kamal N, Abilleira S, Jimenez X, Ramos-Pachon A, Garcia-Tornel A, Perez de la Ossa N, Ribo M, Hill MD, Holodinsky JK. Modeling Prehospital Transportation for Patients With Suspected Acute Ischemic Stroke due to Large Vessel Occlusion: A Validation Study Using the RACECAT Trial Data. Stroke. 2026 Aug;57(8):2340-2347. doi: 10.1161/STROKEAHA.125.054668. Epub 2026 May 13.
- Derived from this study: PubMed 37603325Ramos-Pachon A, Rodriguez-Luna D, Marti-Fabregas J, Millan M, Bustamante A, Martinez-Sanchez M, Serena J, Terceno M, Vera-Caceres C, Camps-Renom P, Prats-Sanchez L, Rodriguez-Villatoro N, Cardona-Portela P, Urra X, Sola S, Del Mar Escudero M, Salvat-Plana M, Ribo M, Abilleira S, Perez de la Ossa N, Silva Y; RACECAT Trial Investigators. Effect of Bypassing the Closest Stroke Center in Patients with Intracerebral Hemorrhage: A Secondary Analysis of the RACECAT Randomized Clinical Trial. JAMA Neurol. 2023 Oct 1;80(10):1028-1036. doi: 10.1001/jamaneurol.2023.2754.
- Derived from this study: PubMed 36848432Garcia-Tornel A, Flores A, Terceno M, Cardona P, Amaro S, Gomis M, Zaragoza J, Krupinski J, Gomez-Choco M, Mas N, Cocho D, Catena E, Purroy F, Deck M, Rubiera M, Pagola J, Rodriguez-Luna D, Juega J, Rodriguez-Villatoro N, Molina CA, Soro C, Jimenez X, Salvat-Plana M, Davalos A, Jovin TG, Abilleira S, Perez de la Ossa N, Ribo M; RACECAT Trial Investigators. Association of Time of Day With Outcomes Among Patients Triaged for a Suspected Severe Stroke in Nonurban Catalonia. Stroke. 2023 Mar;54(3):770-780. doi: 10.1161/STROKEAHA.122.041013. Epub 2023 Feb 27.
- Derived from this study: PubMed 36259411Garcia-Tornel A, Millan M, Rubiera M, Bustamante A, Requena M, Dorado L, Olive-Gadea M, Jimenez X, Soto A, Querol M, Hernandez-Perez M, Gomis M, Cardona P, Urra X, Purroy F, Silva Y, Ustrell X, Esteve P, Salvat-Plana M, Gallofre M, Molina C, Davalos A, Jovin T, Abilleira S, Ribo M, Perez de la Ossa N; RACECAT Trial Investigators. Workflows and Outcomes in Patients With Suspected Large Vessel Occlusion Stroke Triaged in Urban and Nonurban Areas. Stroke. 2022 Dec;53(12):3728-3740. doi: 10.1161/STROKEAHA.122.040768. Epub 2022 Oct 19.
- Derived from this study: PubMed 36053966Garcia-Tornel A, Sero L, Urra X, Cardona P, Zaragoza J, Krupinski J, Gomez-Choco M, Sala NM, Catena E, Palomeras E, Serena J, Hernandez-Perez M, Boned S, Olive-Gadea M, Requena M, Muchada M, Tomasello A, Molina CA, Salvat-Plana M, Escudero M, Jimenez X, Davalos A, Jovin TG, Purroy F, Abilleira S, Ribo M, de la Ossa NP; RACECAT trial investigators. Workflow Times and Outcomes in Patients Triaged for a Suspected Severe Stroke. Ann Neurol. 2022 Dec;92(6):931-942. doi: 10.1002/ana.26489. Epub 2022 Sep 7.
- Derived from this study: PubMed 35510397Perez de la Ossa N, Abilleira S, Jovin TG, Garcia-Tornel A, Jimenez X, Urra X, Cardona P, Cocho D, Purroy F, Serena J, San Roman Manzanera L, Vivanco-Hidalgo RM, Salvat-Plana M, Chamorro A, Gallofre M, Molina CA, Cobo E, Davalos A, Ribo M; RACECAT Trial Investigators. Effect of Direct Transportation to Thrombectomy-Capable Center vs Local Stroke Center on Neurological Outcomes in Patients With Suspected Large-Vessel Occlusion Stroke in Nonurban Areas: The RACECAT Randomized Clinical Trial. JAMA. 2022 May 10;327(18):1782-1794. doi: 10.1001/jama.2022.4404.
- Derived from this study: PubMed 31142219Abilleira S, Perez de la Ossa N, Jimenez X, Cardona P, Cocho D, Purroy F, Serena J, Roman LS, Urra X, Vilaro M, Cortes J, Gonzalez JA, Chamorro A, Gallofre M, Jovin T, Molina C, Cobo E, Davalos A, Ribo M. Transfer to the Local Stroke Center versus Direct Transfer to Endovascular Center of Acute Stroke Patients with Suspected Large Vessel Occlusion in the Catalan Territory (RACECAT): Study protocol of a cluster randomized within a cohort trial. Int J Stroke. 2019 Oct;14(7):734-744. doi: 10.1177/1747493019852176. Epub 2019 May 29.
- Individual participant dataSharing planned: Undecided
Related trials for Stroke
Not yet recruiting
Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
Acute Ischemic Stroke
RecruitingObservational study
ELATE Study: Evaluating Large-vessel Acute Thrombectomy in Extended Time Window
Acute Ichemic Stroke
Recruiting
Web-Based Tele-Rehabilitation Using Action Observation and Mirror Therapy for Subacute Stroke: A Randomized Controlled Trial
Stroke, Upper Extremity Paresis
Recruiting
Early Motor-Cognitive Integrative Training on Cognitive and Motor Performance in Patients With Aneurysmal Subarachnoid Hemorrhage
Subarachnoid Aneurysm Hemorrhage
Not yet recruiting
Selective Intra-Arterial Hypothermia After Endovascular Treatment for Acute Basilar Artery Occlusion
Acute Ischemic Stroke, Basilar Artery Occlusion
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Marc Ribó, PhD principal investigator
Hospital Universitari Vall d'Hebrón, Barcelona, Spain
Sonia Abilleira, PhD principal investigator
Pla Director Malaltia Vascular Cerebral. Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
Natalia Pérez de la Ossa, PhD principal investigator
Hospital Universitari Germans Trias i Pujol, Badalona, Spain
12 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Direct transfer to an Endovascular Center in people with Stroke, run by Fundacio Ictus Malaltia Vascular at 12 sites in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Mar 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 12 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
modified Rankin Scale score (shift analysis) (time frame: 90 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02795962, which also lists 7 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Mar 2021.